Effects of a Dance and Walking Program for People With Parkinson's Disease (DANCEPD)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03370315|
Recruitment Status : Completed
First Posted : December 12, 2017
Last Update Posted : December 28, 2017
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Parkinson Disease||Other: Dance Program Other: Walking Program||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||20 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Investigator, Outcomes Assessor)|
|Official Title:||Effects of a Dance and Walking Program on Gait and Quality of Life in People With Parkinson's Disease|
|Actual Study Start Date :||July 1, 2017|
|Actual Primary Completion Date :||July 1, 2017|
|Actual Study Completion Date :||December 5, 2017|
Experimental: Dance Group
This group will be undergo dance classes two times a week, for 12 weeks. 24 sessions.
Intervention administered: Dance classes inspired by the rhythm of Forró and Samba.
Other: Dance Program
The dance program consists of dance classes inspired by the rhythm of Forró and Samba. The sessions are divided into four stages: 1) stretching and sensitization of the body, with the support of chairs; 2) balance and rhythm exercises, with the support of the bar; 3) dance inspired by the genres worked - Forró and Samba; 4) Fun activities that stimulate socialization or with visual clues, working displacements, motor coordination, rhythm, improvisation and creativity. 24 sessions, twice a week, which session take 60 min.
Experimental: Walking Group
This group will be undergo walking training two times a week, for 12 weeks. 24 sessions.
Intervention administered: Walking program with 3 different moments.
Other: Walking Program
The walking program consists of 3 moments: 1) a brief warm-up of free walking for 3 minutes in the comfortable velocity; 2) then walking according to the training cycle, the intensity will be between 60 and 80% of the reserve heart rate; 3) a relaxation. 24 sessions, twice a week, which session take 60 min.
- The change in functional mobility [ Time Frame: Before and after 12 weeks after the intervention ]The functional mobility will be assessed using the Timed Up and Go Test. This first outcome will be evaluated before and after 12 weeks of Dance Classes and Walking Training in both groups.
- The change in the gait specific parameters [ Time Frame: Before and after 12 weeks after the intervention ]The gait specific parameters will be assessed using the BTS SMART DX 7000. This secondary outcome will be evaluated before and after 12 weeks of Dance Classes and Walking Training in both groups.
- The change in Quality of Life [ Time Frame: Before and after 12 weeks after the intervention ]Quality of Life will be assessed using Parkinsons' Disease Questionnaire (PDQ-39). The Quality of Life questionnaire will be evaluated before and after 12 weeks of Dance Classes and Walking Training in both groups. Parkinson's Disease Questionnaire (PDQ39) measures patients' quality of life through 39 questions. The instrument is divided into eight dimensions: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication and bodily discomfort. In total, patients answer 39 questions that should be noted among five response options: "never," "rarely," "sometimes," "often" or "always."
- The change in motor symptoms [ Time Frame: Before and after 12 weeks after the intervention ]Motor symptoms will be assessed using Unified Parkinsons' Disease Rating Scale (UPDRS). The motor symptoms will be evaluated before and after 12 weeks of Dance Classes and Walking Training in both groups. We will use the Part III of the Unified Parkinson's Disease Rating Scale (UPDRS III), which measures the motor symptoms of the disease. Part III of the UPDRS is composed of 14 items, covering questions 18 to 31 of the scale. Each item has 5 response options that add up to 0 to 4 points, how bigger is the total score on the scale; greater is the patient's motor impairment.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||50 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Both sex;
- Equal to or more than 50 years old;
- Parkinson Disease in regular medical treatment and follow-up;
- Illness diagnosis equal to or more than one year;
- H&Y scale between one and three;
- Able to walk independently or with a walking stick.
- More than six absences in dance class or in the walking training (25%);
- Start a new activity parallel to the project;
- Risk factors: Recent surgeries, Deep brain stimulation surgery (DBS), Other associated neurological diseases or other chronic diseases.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03370315
|Universidade Federal do Rio Grande do Sul|
|Porto Alegre, Rio Grande Do Sul, Brazil|
|Principal Investigator:||Aline N. Haas, PhD||Federal University of Rio Grande do Sul|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
|Responsible Party:||Aline Nogueira Haas, Principal Investigator, Federal University of Rio Grande do Sul|
|Other Study ID Numbers:||
|First Posted:||December 12, 2017 Key Record Dates|
|Last Update Posted:||December 28, 2017|
|Last Verified:||December 2017|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Quality of Life
Basal Ganglia Diseases
Central Nervous System Diseases
Nervous System Diseases